Cell Based Assays Market

The cell-based assays market is projected to reach USD 24.3 billion by 2029 from an estimated USD 17.3 billion in 2024, at a CAGR of 7.1% during the forecast period of 2024 to 2029. Growth in the cell-based assays market can be attributed to factors such as the growing demand for drug discovery & development and the increasing preference for cell-based assays in drug discovery, government support and funding for cell-based research, and growing efforts by the FDA to curtail animal-based studies. The rising prevalence of cancer also drives the growth of the cell-based assays market. The growing adoption of strategic alliances to accelerate innovations in drug discovery is also anticipated to promote growth in the cell-based assays market. Moreover, the growing applications of cell-based assays in chronic diseases and personalized medicine are likely to support the growth of the market in the coming years. However, the high cost of instruments and restrictions imposed by product end-user licenses for reagents may hamper the growth of the market.

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Cell-based Assays Market

Global Cell-based Assays Market Dynamics

Driver: Growing government support and funding for cell-based research

Cell-based assays are used to quantify cell viability, cell health, cell proliferation, and cell apoptosis. They are widely used in drug discovery and development. A major factor driving market growth is the increasing funding and investments for developing advanced cell-based therapeutics. Additionally, growing government support to accelerate cell-based research is another key factor driving the growth of the cell-based assays market. In August 2023, the National Research Fund (NRF) provided USD 0.53 million (KES 77.2 million) to Kenya Medical Research Institute (KEMRI) for the establishment of KEMRl's National Reference Laboratory for Stem Cell Research. Such developments are expected to support market growth in the coming years.

Restraint: High cost of instruments and restrictions imposed by product end-user licenses for reagents

High cost of cell-based products such as instruments and software is hampering the growth of the market. The integration of advanced technologies such as high throughput screening and high content screening in cell-based assays has increased their reliability. However, the initial investment cost associated with the instruments is limiting the adoption of these technologies by the small research facilities and resource. Additionally, the tome and cost of high throughput screening is directly proportional to the target molecule complexities, higher is the complexity, the grater the cost. Therefore, high cost of instruments might hinder the growth of the market.

Opportunity: Growing applications of cell-based assays in personalized medicine

Cell-based assays are widely used for drug discovery and basic research. The wide applications of cell-based assays in drug discovery are expected to create significant growth opportunities for players in the market. Additionally, cell-based assays provide valuable insights into the mechanism of cells associated with chronic diseases and offer more accurate disease management and drug development approaches. In cancer research, cell-based assays are used to study the response of tumor cells to potential treatment. Thus, the growing applications of cell-based assays in the management of chronic conditions are anticipated to support market growth in the coming years.

Challenge: Complexities in assay designs

Cell-based assays are associated with some complexities in assay design due to interactions in cellular factors and processes. The development of accurate and reliable assays to provide precise data is a complex task. Complexities with assay design arise due to various factors, such as cell type selection, assay protocols, culture conditions, and endpoint measurement. Designing assays that can mimic complex cellular environments requires careful consideration and optimization. However, incorporating relevant and appropriate controls can help minimize assay design complexities.

Global Cell-based Assays Ecosystem Analysis

The cell-based assays market ecosystem comprises raw material suppliers, cell-based assay product & service providers, and end users, such as pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutes. Cell-based assay product manufacturers provide consumables, instruments, and software.

The consumables segment dominated the cell-based assays market in 2023.

Based on offerings, the cell-based assays market is segmented into consumables, instruments, software, and services. The consumables segment is further categorized into reagents, assay kits, microplates, cell lines, probes & labels, and other consumables. In 2023, the consumables segment accounted for a major market share due to the growing need for high-quality reagents to develop advanced cell-based therapies. The increasing demand for personalized medicine and cell-based therapeutics due to the rising incidence of cancer is also expected to support the growth of the cell-based assays market.

The toxicity studies segment accounted for the largest share of the drug discovery segment in the cell-based assays market in 2023.

Based on applications, the cell-based assays market is segmented into drug discovery, basic research, genetic studies, and other applications. The drug discovery segment is further divided into toxicity studies, pharmacokinetics, and pharmacodynamics. In 2023, toxicity studies accounted for the largest share of the drug discovery market segment. The rising need for cell-based assays for the evaluation of toxicity studies primarily drives growth in this segment. Additionally, the adoption of high-content screening technologies, such as cell-based assays for toxicity testing, is expected to propel the growth of the segment.

North America dominated the cell-based assays market in 2023.

To know about the assumptions considered for the study, download the pdf brochure

The global cell-based assays market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America accounted for the largest share of the cell-based assays market in 2023, followed by Europe and the Asia Pacific. Factors such as the increasing development and manufacturing of cell-based therapies, significant investments in research & development activities, and the presence of a well-established healthcare sector are responsible for the large share of the North American region in the cell-based assays market.

Key Market Players

The key players in the cell-based assays market include BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Revvity (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg) , Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), Altogen Labs (US), and BioAgilytix (US).

Want to explore hidden markets that can drive new revenue in Cell Based Assays Market?

Unlock Insights

Click on image to enlarge

Scope of the Report

This report categorizes the cell-based assays market into the following segments:

Cell-Based Assays Market, by Offering

• Consumables
  • Reagents
  • Assay Kits
    • Reporter Gene Assays
    • Cell Growth Assays
    • Second Messenger Assays
    • Cell Death Assays
    • Other Assay Kits
  • Microplates
  • Cell Lines
    • Immortalized Cell Lines
    • Primary Cell Lines
    • Stem Cell Lines
  • Probes & Labels
  • Other Consumables
• Instruments
• Software
• Services

Cell-Based Assays Market, by Technology

• Flow Cytometry
• High Throughput Screening
• Label free Detection
• Other Technologies

Cell-Based Assays Market, by Application

• Drug Discovery
  • Toxicity Studies
  • Pharmacokinetic Studies
  • Pharmacodynamic Studies
• Basic Research
• Genetic Studies
• Other Applications

Cell-Based Assays Market, by End User

• Pharmaceutical & Biotechnlogy Companies
• Contract research Organizations (CROs)
• Academic & Research Institutes

Cell-Based Assays Market, by Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East
  • GCC Countries
    • Saudi Arabia (KSA)
    • United Arab Emirates (UAE)
    • Rest of GCC Countries (RoGCC)
  • Rest of Middle East (RoME)
• Africa

Recent Developments

• In April 2024, BD launched the BD FACSDiscover S8 Cell Sorters to enable researchers to expand their research into fields like cell biology, cancer research, and immunology.
• In October 2023, Danaher Corporation (Beckman Coulter Life Sciences) partnered with 10x Genomics to expand automation solutions for single-cell assay workflows.
• In February 2023, Agilent Technologies, Inc. launched the xCELLigence RTCA HT (real-time cell analysis high throughput) platform, which is integrated with the BioTek BioSpa 8 Automated Incubator.
• In January 2023, Charles River Laboratories acquired SAMDI Tech, which offers label-free HTS solutions for drug discovery research. The acquisition offered CRL expertise in label-free HTS MS platforms and created a comprehensive library of drug discovery solutions.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst